Authors summarize the results and perspectives of therapeutic complement inhibition aiming to suppress the activation of an important effector mechanism of the immunity, the serum complement system. It seems most probable that complement suppression therapy will be used in the clinical practice in the near future. According to some recent findings, widespread used drugs like heparin or intravenous immunoglobulin act at least partly through the inhibition of complement activation. Other drugs were developed with aim to suppress the complement system. Therapeutic trials are already in progress with some of these drugs and a constant increase of the phase I, phase II and even phase III trials with these drugs is expected. In the first part the structure, biochemical function, activation pathways of the complement system as well as the biologically active and pathologically important fragments of the complement proteins are shortly described. Then observations obtained in patients and findings of animal experiments supporting the essential role of complement activation in the pathomechanism of several human diseases are summarized. Since most of these diseases are frequent and severe, it seemed worthwhile to develop drugs for suppressing complement activation and thus influencing the course of these diseases in favorable direction. The potential dangers of the complement inhibition therapy are also detailed. In the second part of the review, groups of drugs suitable for the complement inhibition therapy and the most important results achieved with these drugs are summarized.
|Translated title of the contribution||Possibilities for the therapeutic manipulation of the plasma complement system|
|Number of pages||8|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Jun 30 1999|
ASJC Scopus subject areas